Rare Cancer News & Clinical Trials » Trials - Gall Bladder Cancer

Feeds

20859 items (20859 unread) in 74 feeds

Acinar Cell Carcinoma (201 unread)

• Google - Acinar Cell Carcinoma (140 unread)
• PubMed - Acinar Cell Carcinoma (59 unread)
• Trial - Acinar Cell Carcinoma (2 unread)

Acinic Cell Carcinoma (104 unread)

• Google - Acinic Cell Carcinoma (34 unread)
• PubMed - Acinic Cell Carcinoma (70 unread)
• Trial - Acinic Cell Carcinoma

Adenoid Cystic Carcinoma (367 unread)

• Google - Adenoid Cystic Carcinoma (242 unread)
• PubMed - Adenoid Cystic Carcinoma (115 unread)
• Trial - Adenoid Cystic Carcinoma (10 unread)

Adrenal Gland Cancer (1718 unread)

• Google - Adrenal Cancer (925 unread)
• Google - Adrenocortical Carcinoma (317 unread)
• PubMed - Adrenal Cancer (315 unread)
• PubMed - Adrenocortical Carcinoma (108 unread)
• Trial - Adrenal Cancer (42 unread)
• Trial - Adrenocortical Carcinoma (11 unread)

Ampulla Of Vater (213 unread)

• Google - Ampullary Cancer (127 unread)
• PubMed - Ampullary Cancer (80 unread)
• Trial - Ampullary Carcinoma (6 unread)

Anal Cancer (1799 unread)

• Google - Anal Cancer (983 unread)
• PubMed - Anal Cancer (769 unread)
• Trial - Anal Cancers (47 unread)

Angiosarcoma (359 unread)

• Google - Angiosarcoma (185 unread)
• PubMed - Angiosarcoma (164 unread)
• Trial - Angiosarcoma (10 unread)

Appendix Cancer (450 unread)

• Google - Appendix Cancer (334 unread)
• PubMed - Appendix Cancer (100 unread)
• Trial - Appendix Cancer (16 unread)

Bile Duct Cancer (2698 unread)

• Google - Bile Duct Cancer (951 unread)
• Google - Cholangiocarcinoma (691 unread)
• PubMed - Bile Duct Cancer (271 unread)
• PubMed - Cholangiocarcinoma (628 unread)
• Trial - Bile Duct Cancer (84 unread)
• Trial - Cholangiocarcinoma (73 unread)

Brain and CNS (2597 unread)

• Google - Rare Brain Tumor (889 unread)
• Google - Rare CNS Tumor (725 unread)
• PubMed - Ganglioglioma (56 unread)
• PubMed - Rare Brain Tumor (264 unread)
• PubMed - Rare CNS Tumor (164 unread)
• Trial - Brain Tumor (291 unread)
• Trial - CNS Tumor (203 unread)
• Trial - Ganglioglioma (5 unread)

Carcinoid (671 unread)

• Google - Carcinoid (471 unread)
• PubMed - Carcinoid (193 unread)
• Trials - Carcinoid (7 unread)

Endocrine/Neuroendocrine (2404 unread)

• Google - Merkel Cell Cancer (370 unread)
• Google - Neuroendocrine Tumor (853 unread)
• PubMed - Merkel Cell Cancer (102 unread)
• PubMed - Neuroendocrine Tumor (889 unread)
• Trial - Merkel Cell Cancer (23 unread)
• Trial - Neuroendocrine Cancers (167 unread)

Gall Bladder Cancer (1146 unread)

• Google - Gall Bladder Cancer (1001 unread)
• PubMed - Gall Bladder Cancer (126 unread)
• Trials - Gall Bladder Cancer (19 unread)

Hemangioendothelioma (506 unread)

• Google - Hemangioendothelioma (109 unread)
• PubMed - Hemangioendothelioma (392 unread)
• Trial - Hemangioendothelioma (5 unread)

Hepatoblastoma (366 unread)

• Google - Hepatoblastoma (259 unread)
• PubMed - Hepatoblastoma (96 unread)
• Trial - Hepatoblastoma (11 unread)

Pancreas (416 unread)

• Google - Insulinoma (327 unread)
• PubMed - Insulinoma (86 unread)
• Trial - Insulinoma (3 unread)

Phyllodes (215 unread)

• Google - Phyllodes Tumor (127 unread)
• PubMed - Phyllodes Tumor (88 unread)
• Trial - Phyllodes

PMP and Mucinous Tumors (242 unread)

• Google - Pseudomyxoma Peritonei (176 unread)
• PubMed - Pseudomyxoma Peritonei (PMP) (64 unread)
• Trial - Pseudomyxoma Peritonei (2 unread)

Rhabdomyosarcoma (772 unread)

• Google - Rhabdomyosarcoma (572 unread)
• PubMed - Rhabdomyosarcoma (176 unread)
• Trial - Rhabdomyosarcoma (24 unread)

Sarcoma (3615 unread)

• Google - Sarcoma (1622 unread)
• PubMed - Sarcoma (1742 unread)
• Trial - Sarcoma (251 unread)

Trials - Gall Bladder Cancer (19 unread)

• 

  Study Comparing Standard of Care Therapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels

  Posted: June 18th, 2021, 2:00pm GMT

  Conditions:   Metastatic Cancer;   Foregut Carcinoid Tumor;   Gastric Adenocarcinoma;   Gallbladder Adenocarcinoma;   Liver Cancer;   GI Cancer;   GI Carcinoma;   Lung Cancer
  Interventions:   Drug: Standard of Care Chemotherapy;   Procedure: Video-Assisted Thoracic Surgery (VATS);   Procedure: Lobectomy;   Radiation: Consolidative Radiation;   Radiation: Ablation Treatment;   Procedure: Resection or Excision;   Procedure: Peritonectomy;   Other: Transarterial Radioembolization
  Sponsor:   University of Chicago
  Not yet recruiting
• 

  Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study

  Posted: June 11th, 2021, 2:00pm GMT

  Condition:   Biliary Tract Carcinoma
  Interventions:   Biological: Pembrolizumab;   Drug: Gemcitabine;   Drug: Cisplatin;   Drug: Placebo
  Sponsor:   Merck Sharp & Dohme Corp.
  Recruiting
• 

  EUS-Guided Choledochoduodenostomy Versus ERCP for Primary Biliary Decompression in Distal Malignant Biliary Obstruction

  Posted: May 24th, 2021, 2:00pm GMT

  Condition:   Malignant Biliary Obstruction
  Intervention:   Procedure: Biliary drainage
  Sponsor:   Mansoura University
  Recruiting
• 

  New Prospective Expanded German Registry of Incidental Gallbladder Carcinoma (PERSUASION)- a Permanent Platform Including All Kind of Biliary Tract Cancers (BTC)

  Posted: May 21st, 2021, 2:00pm GMT

  Conditions:   Biliary Tract Cancer;   Neoadjuvant, Adjuvant and 1st Line
  Intervention:  
  Sponsor:   Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
  Not yet recruiting
• 

  Biomarker Discovery in Patients With Advanced Biliary Tract Cancer

  Posted: May 4th, 2021, 2:00pm GMT

  Conditions:   Biliary Tract Cancer;   Cholangiocarcinoma;   Gallbladder Cancer
  Intervention:   Drug: nab-paclitaxel plus gemcitabine-cisplatin
  Sponsors:   CHA University;   Dong-A Pharmaceutical
  Recruiting
• 

  A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection

  Posted: April 23rd, 2021, 2:00pm GMT

  Conditions:   Biliary Tract Neoplasms;   Recurrence;   Cholangiocarcinoma;   Gall Bladder Cancer
  Interventions:   Drug: S-1;   Drug: Capecitabine
  Sponsor:   Fudan University
  Recruiting
• 

  A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumor

  Posted: April 21st, 2021, 2:00pm GMT

  Conditions:   Minimal Residual Disease;   KRAS G12D;   KRAS G12R;   NRAS G12D;   NRAS G12R;   Pancreatic Ductal Adenocarcinoma;   Colorectal Cancer;   Non-small Cell Lung Cancer;   Ovarian Cancer;   Cholangiocarcinoma;   Bile Duct Cancer;   Gallbladder Carcinoma
  Interventions:   Drug: ELI-002 (Dose Escalation);   Drug: ELI-002 (at the RP2D);   Other: Observation
  Sponsor:   Elicio Therapeutics
  Recruiting
• 

  Pamiparib and Low Dose Temozolomide In Patients With Platinum Sensitive Biliary Tract Cancer

  Posted: March 12th, 2021, 3:00pm GMT

  Condition:   Platinum-Sensitive Biliary Tract Cancer
  Interventions:   Drug: Cisplatin;   Drug: Gemcitabine;   Drug: Oxaliplatin;   Drug: Pamiparib;   Drug: Temozolomide
  Sponsor:   European Organisation for Research and Treatment of Cancer - EORTC
  Not yet recruiting
• 

  Study of TT-00420 Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

  Posted: February 8th, 2021, 3:00pm GMT

  Conditions:   Advanced Solid Tumor;   Cholangiocarcinoma;   HER2-negative Breast Cancer;   Triple Negative Breast Cancer;   Bladder Cancer;   Small-cell Lung Cancer;   Prostate Cancer;   Thyroid Cancer;   Sarcoma;   Gastric Cancer;   Gallbladder Cancer
  Interventions:   Drug: TT-00420;   Combination Product: Nab-Paclitaxel
  Sponsor:   TransThera Biosciences Co., Ltd
  Not yet recruiting
• 

  Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer

  Posted: September 23rd, 2020, 2:00pm GMT

  Conditions:   Biliary Tract Cancer;   Cholangiocarcinoma;   Gallbladder Cancer;   Intrahepatic Cholangiocarcinoma;   Perihilar Cholangiocarcinoma;   Extrahepatic Cholangiocarcinoma;   Hilar Cholangiocarcinoma;   Distal Bile Duct Cancer
  Intervention:   Diagnostic Test: Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring
  Sponsors:   University of Washington;   Natera, Inc.;   SEngine Precision Medicine, Inc.
  Recruiting
• 

  A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

  Posted: July 31st, 2020, 2:00pm GMT

  Condition:   Advanced Cancer
  Intervention:   Biological: TST001 injection
  Sponsors:   Mabspace Biosciences (Suzhou) Co., Ltd.;   Beijing Cancer Hospital;   First Affiliated Hospital of Zhejiang University;   Fudan University;   Henan Cancer Hospital;   Second Affiliated Hospital, School of Medicine, Zhejiang University;   Tianjin Medical University Cancer Institute and Hospital;   First Affiliated Hospital Bengbu Medical College;   The First People's Hospital of Jingzhou;   Sixth Affiliated Hospital, Sun Yat-sen University;   Beijing Friendship Hospital;   General Hospital of Tianjin Medical University
  Recruiting
• 

  Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

  Posted: May 12th, 2020, 2:00pm GMT

  Conditions:   Locally Advanced Solid Tumor;   Metastatic Solid Tumor;   Pancreatic Cancer;   Lung Cancer;   Head and Neck Cancer;   Breast Cancer;   Kidney Cancer;   Colorectal Cancer;   Bladder Cancer;   Ovarian Cancer;   Sarcoma;   Gallbladder Cancer;   Bile Duct Cancer;   Esophageal Cancer;   Uterine Cancer;   Cholangiocarcinoma;   Prostate Cancer
  Intervention:   Drug: Seribantumab
  Sponsor:   Elevation Oncology
  Recruiting
• 

  Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)

  Posted: December 18th, 2019, 3:00pm GMT

  Condition:   Biliary Tract Cancer
  Interventions:   Drug: CPI 613;   Drug: Gemcitabine;   Drug: Cisplatin
  Sponsor:   University of Michigan Rogel Cancer Center
  Recruiting
• 

  Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L Biliary Tract Cancer (BTC)

  Posted: August 26th, 2019, 2:00pm GMT

  Conditions:   Biliary Tract Cancer;   Cholangiocarcinoma;   Gallbladder Cancer
  Interventions:   Drug: Bintrafusp alfa;   Drug: Placebo;   Drug: Gemcitabine;   Drug: Cisplatin
  Sponsors:   EMD Serono Research & Development Institute, Inc.;   Merck KGaA, Darmstadt, Germany
  Recruiting
• 

  A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients

  Posted: November 7th, 2018, 3:00pm GMT

  Condition:   Cancer
  Intervention:   Biological: FP-1305
  Sponsor:   Faron Pharmaceuticals Ltd
  Recruiting
• 

  Pembrolizumab in Biliary Tract Cancer

  Posted: August 24th, 2017, 2:00pm GMT

  Conditions:   Biliary Tract Cancer;   Metastatic Cancer;   Advanced Cancer;   Gallbladder Cancer
  Interventions:   Drug: Pembrolizumab;   Drug: Cisplatin;   Drug: Gemcitabine
  Sponsor:   European Organisation for Research and Treatment of Cancer - EORTC
  Recruiting
• 

  Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies

  Posted: February 6th, 2017, 3:00pm GMT

  Conditions:   Cholangiocarcinoma Non-resectable;   Cholangiocarcinoma Metastatic;   Cholangiocarcinoma of the Gallbladder;   Cholangiocarcinoma Advanced
  Interventions:   Drug: nal-IRI;   Drug: 5-FU;   Drug: leucovorin
  Sponsors:   AIO-Studien-gGmbH;   Servier
  Recruiting
• 

  Hepatic Resection for Metastatic Pancreatic Cancer

  Posted: September 8th, 2016, 2:00pm GMT

  Conditions:   Pancreatic Neoplasms;   Neoplasm Metastasis;   Liver Metastases
  Intervention:   Procedure: Hepatic Resection or Ablation with Pancreaticoduodenectomy
  Sponsor:   Duke University
  Recruiting
• 

  Acquisition of Blood and Tumor Tissue Samples From Patients With Gastrointestinal Cancer

  Posted: March 11th, 2011, 3:00pm GMT

  Conditions:   Non-GI Cancers;   Cancer of Gastrointestinal Tract;   Gastrointestinal Cancer
  Intervention:  
  Sponsor:   National Cancer Institute (NCI)
  Recruiting